×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. I consent to receive medical updates and communications from eMediNexus, it's parent company IJCP and its industry partners.

NefIgArd trial

  946 Views

eMediNexus    27 February 2023

 

REFERENCE-

 

Barratt J, Lafayette R, Kristensen J. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney International. 2023;103(2):391-402. DOI:https://doi.org/10.1016/j.kint.2022.09.017

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.